abstract |
The present invention is directed to gremlin-1 having a therapeutic effect on cancer by inhibiting gremlin-1 in a manner independent of bone morphogenetic protein (BMP) or vascular endothelial growth factor receptor-2 (VEGFR2). The antibody according to the present invention relates to a cancer or immune disease by suppressing cell migration, cell invasion and cell proliferation dependent on gremlin-1 It is suitably used for treating. [Selection] Figure 1 |